Giovannoni, Gavin http://orcid.org/0000-0001-9995-1700
Comi, Giancarlo http://orcid.org/0000-0002-6989-1054
Rammohan, Kottil http://orcid.org/0000-0003-2467-4280
Rieckmann, Peter
Dangond, Fernando http://orcid.org/0000-0002-6723-4229
Keller, Birgit http://orcid.org/0000-0001-6870-8003
Jack, Dominic http://orcid.org/0000-0001-8629-553X
Vermersch, Patrick http://orcid.org/0000-0003-0997-8817
Clinical trials referenced in this document:
Documents that mention this clinical trial
Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies
https://doi.org/10.1007/s12325-021-01865-w
Documents that mention this clinical trial
022 Updated safety of cladribine tablets in multiple sclerosis patients: integrated safety analysis and post-approval data
https://doi.org/10.1136/jnnp-2022-abn.61
Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies
https://doi.org/10.1007/s12325-021-01865-w
Funding for this research was provided by:
Merck KGaA (CrossRef Funder ID: 10.13039/100009945)
Article History
Received: 7 April 2021
Accepted: 16 July 2021
First Online: 9 August 2021